GlaxoSmithKline Is Mouthful But Still Hungry: Is Next Course Japanese?
Executive Summary
GlaxoSmithKline's acquisition strategy will concentrate on medium-sized pharmaceutical and biotech companies with a pipeline, CEO J.P. Garnier told analysts during a Feb. 22 meeting in London.
You may also be interested in...
GSK Decreases Reliance On Late-Stage Licenses, Citing Strength In R&D
GlaxoSmithKline is reducing its reliance on late-stage in-licensing deals following an R&D restructuring program that has yielded a burgeoning pipeline, CEO J.P. Garnier told analysts
GSK Decreases Reliance On Late-Stage Licenses, Citing Strength In R&D
GlaxoSmithKline is reducing its reliance on late-stage in-licensing deals following an R&D restructuring program that has yielded a burgeoning pipeline, CEO J.P. Garnier told analysts
Schering Hunting Biotech Deals To Complement Specialty Portfolio
Schering-Plough is focusing its in-licensing activities on specialty biotechnology products, CEO Fred Hassan told analysts during the company's business review in New York City Nov. 18